Telomir Pharmaceuticals (NASDAQ: TELO) reported new research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibited growth across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. The results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
The ability of Telomir-Zn to produce comparable growth inhibition in both human and canine osteosarcoma models at low concentrations is significant because it suggests a conserved mechanism of action across species. Canine osteosarcoma is a naturally occurring disease that shares many clinical, biological, and genetic features with human osteosarcoma. This makes it a valuable translational model for studying new therapies. If the drug's effects are confirmed in vivo, it could accelerate development for both veterinary and human applications, potentially leading to treatments for a rare and aggressive cancer that disproportionately affects children and young adults.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. The company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared IND for advanced or metastatic TNBC. This dual focus on oncology programs highlights the company's strategy to leverage its small-molecule platform across multiple cancer types.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The new osteosarcoma findings add to the growing body of evidence supporting Telomir-Zn's potential as a broad anticancer agent.
For investors, the announcement signals progress in expanding the potential applications of Telomir-Zn beyond its lead indication. Osteosarcoma is a rare disease with limited treatment options, especially for metastatic or recurrent cases. A successful canine study could provide proof-of-concept data that might de-risk further development and attract additional interest. However, the company remains focused on its TNBC program, which is the most advanced and closest to clinical milestones. The news also underscores the value of comparative oncology, where naturally occurring cancers in pets can inform human drug development, potentially saving time and resources.
To view the full press release, visit https://nnw.fm/laeGH. For more information and updates, visit the company's newsroom at https://nnw.fm/TELO.
